703 related articles for article (PubMed ID: 26068908)
1. Mapping the solid-state properties of crystalline lysozyme during pharmaceutical unit-operations.
Mohammad MA; Grimsey IM; Forbes RT
J Pharm Biomed Anal; 2015 Oct; 114():176-83. PubMed ID: 26068908
[TBL] [Abstract][Full Text] [Related]
2. Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats.
Nielsen LH; Gordon S; Holm R; Selen A; Rades T; Müllertz A
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):942-51. PubMed ID: 24075980
[TBL] [Abstract][Full Text] [Related]
3. Stability of crystallised and spray-dried lysozyme.
Elkordy AA; Forbes RT; Barry BW
Int J Pharm; 2004 Jul; 278(2):209-19. PubMed ID: 15196626
[TBL] [Abstract][Full Text] [Related]
4. X-ray powder diffractometry in combination with principal component analysis--a tool for monitoring solid state changes.
Kogermann K; Veski P; Rantanen J; Naelapää K
Eur J Pharm Sci; 2011 Jul; 43(4):278-89. PubMed ID: 21575718
[TBL] [Abstract][Full Text] [Related]
5. Compare and contrast the effects of surfactants (PluronicF-127 and CremophorEL) and sugars (β-cyclodextrin and inulin) on properties of spray dried and crystallised lysozyme.
Haj-Ahmad RR; Elkordy AA; Chaw CS; Moore A
Eur J Pharm Sci; 2013 Jul; 49(4):519-34. PubMed ID: 23712374
[TBL] [Abstract][Full Text] [Related]
6. Study of protein conformational stability and integrity using calorimetry and FT-Raman spectroscopy correlated with enzymatic activity.
Elkordy AA; Forbes RT; Barry BW
Eur J Pharm Sci; 2008 Feb; 33(2):177-90. PubMed ID: 18207710
[TBL] [Abstract][Full Text] [Related]
7. Integrity of crystalline lysozyme exceeds that of a spray-dried form.
Elkordy AA; Forbes RT; Barry BW
Int J Pharm; 2002 Oct; 247(1-2):79-90. PubMed ID: 12429487
[TBL] [Abstract][Full Text] [Related]
8. Disproportionation of a crystalline citrate salt of a developmental pharmaceutical compound: characterization of the kinetics using pH monitoring and online Raman spectroscopy plus quantitation of the crystalline free base form in binary physical mixtures using FT-Raman, XRPD and DSC.
Skrdla PJ; Zhang D
J Pharm Biomed Anal; 2014 Mar; 90():186-91. PubMed ID: 24378612
[TBL] [Abstract][Full Text] [Related]
9. Preparation and characterisation of spray-dried and crystallised trypsin: FT-Raman study to detect protein denaturation after thermal stress.
Forbes RT; Barry BW; Elkordy AA
Eur J Pharm Sci; 2007 Mar; 30(3-4):315-23. PubMed ID: 17236751
[TBL] [Abstract][Full Text] [Related]
10. Influence of protein on mannitol polymorphic form produced during co-spray drying.
Hulse WL; Forbes RT; Bonner MC; Getrost M
Int J Pharm; 2009 Dec; 382(1-2):67-72. PubMed ID: 19682563
[TBL] [Abstract][Full Text] [Related]
11. Characterization of polymorphic ampicillin forms.
Baraldi C; Tinti A; Ottani S; Gamberini MC
J Pharm Biomed Anal; 2014 Nov; 100():329-340. PubMed ID: 25194347
[TBL] [Abstract][Full Text] [Related]
12. Effect of milling conditions on the solid-state conversion of ranitidine hydrochloride form 1.
Chieng N; Zujovic Z; Bowmaker G; Rades T; Saville D
Int J Pharm; 2006 Dec; 327(1-2):36-44. PubMed ID: 16949221
[TBL] [Abstract][Full Text] [Related]
13. Supercritical fluid assisted atomization introduced by an enhanced mixer for micronization of lysozyme: Particle morphology, size and protein stability.
Du Z; Guan YX; Yao SJ; Zhu ZQ
Int J Pharm; 2011 Dec; 421(2):258-68. PubMed ID: 22001535
[TBL] [Abstract][Full Text] [Related]
14. Preparation and characterization of spray-dried co-amorphous drug-amino acid salts.
Jensen KT; Blaabjerg LI; Lenz E; Bohr A; Grohganz H; Kleinebudde P; Rades T; Löbmann K
J Pharm Pharmacol; 2016 May; 68(5):615-24. PubMed ID: 26245703
[TBL] [Abstract][Full Text] [Related]
15. Physical characterization and stability of amorphous indomethacin and ranitidine hydrochloride binary systems prepared by mechanical activation.
Chieng N; Aaltonen J; Saville D; Rades T
Eur J Pharm Biopharm; 2009 Jan; 71(1):47-54. PubMed ID: 18644443
[TBL] [Abstract][Full Text] [Related]
16. An example of how to handle amorphous fractions in API during early pharmaceutical development: SAR114137--a successful approach.
Petzoldt C; Bley O; Byard SJ; Andert D; Baumgartner B; Nagel N; Tappertzhofen C; Feth MP
Eur J Pharm Biopharm; 2014 Apr; 86(3):337-50. PubMed ID: 24075979
[TBL] [Abstract][Full Text] [Related]
17. Differential scanning calorimetry predicts the critical quality attributes of amorphous glibenclamide.
Mah PT; Laaksonen T; Rades T; Peltonen L; Strachan CJ
Eur J Pharm Sci; 2015 Dec; 80():74-81. PubMed ID: 26296864
[TBL] [Abstract][Full Text] [Related]
18. Unravelling the relationship between degree of disorder and the dissolution behavior of milled glibenclamide.
Mah PT; Laaksonen T; Rades T; Aaltonen J; Peltonen L; Strachan CJ
Mol Pharm; 2014 Jan; 11(1):234-42. PubMed ID: 24224572
[TBL] [Abstract][Full Text] [Related]
19. Raman and thermal analysis of indomethacin/PVP solid dispersion enteric microparticles.
Fini A; Cavallari C; Ospitali F
Eur J Pharm Biopharm; 2008 Sep; 70(1):409-20. PubMed ID: 18621516
[TBL] [Abstract][Full Text] [Related]
20. Amino acids as co-amorphous stabilizers for poorly water soluble drugs--Part 1: preparation, stability and dissolution enhancement.
Löbmann K; Grohganz H; Laitinen R; Strachan C; Rades T
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):873-81. PubMed ID: 23537574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
